1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Baseline data on randomization
Randomized Treatment
Hydrogel Bare Platinum
No. % No. %
Total No. patients randomized 249 250 
Sex 
    Female 176 70.7 174 69.6
    Male 73 29.3 76 30.4
Age (years) 
     <45 80 32.1 78 31.2
    46–55 68 27.3 75 30.0
     >55 101 40.6 97 38.8
Target aneurysm size (maximal dimension) 
    2–4.9 mm 42 16.9 41 16.4
    5–9.9 mm 144 57.8 144 57.6
    10–24.9 mm 63 25.3 65 26.0
Dome-to-neck ratio 
     <1.5 83 33.3 81 32.4
     >1.5 166 66.7 169 67.6
Baseline rupture status 
    Yes, in previous 30 days 132 53.0 133 53.2
    Yes, >30 days ago 5 2.0 4 1.6
    Yes, but date unknown 2 0.8 1 0.4
    No 110 44.2 112 44.8
Aneurysm shape 
    Irregular (multilobulated) 76 30.5 77 30.8
    Not multilobulated 173 69.5 173 69.2
Planned use of assist device 
    Yes 112 45.0 115 46.0
    No 122 49.0 121 48.4
    Missing (see “Results”) 15 6.0 14 5.6
Assist device actually used ^* 116 46.6 115 46.0
    Balloon 65 26.1 60 24.0
    Stent 46 18.5 52 20.8
    Other (TriSpan^† double microcatheter techniques) 3 1.2 3 1.2
    Assist device attempted but failed 2 0.8 0 0
    Not known (consent withdrawn) 1 0.4 0 0
    None 131 137 
Randomized Americas^‡ 
    Yes 89 35.7 89 35.6
    No 160 64.3 161 64.4
* More than 1 assist device may have been used in any individual case.
† Boston Scientific, Natick, Mass.
‡ This is North and South America combined.